Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 12/20 | 0.53 |
| ▸ | NPY1R | P25929 | 8/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20827913 | 1.00 | CAPN1 (0.55) | CAPN1CTSLNPY4RNPY1RNPY5R | |
| SCHEMBL20827875 | 1.00 | CAPN1 (0.55) | CAPN1CTSLNPY4RNPY1RNPY5R | |
| SCHEMBL20827895 | 0.96 | CTSK (0.52) | CAPN1CTSLCTSBCTSK | |
| SCHEMBL20827885 | 0.92 | CAPN1 (0.66) | CAPN1CTSLNPY4RNPY1RNPY5R | |
| SCHEMBL20827908 | 0.92 | CAPN1 (0.66) | CAPN1CTSLNPY4RNPY1RNPY5R | |
| SCHEMBL20816652 | 0.91 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20816583 | 0.91 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20816842 | 0.91 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20816685 | 0.90 | KISS1R (0.56) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20828052 | 0.90 | CTSK (0.53) | CAPN1CTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | Phelix Therapeutics (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | CTSS, CTSB, CTSL | CAPN1 8/4885CTSL 3/4885NPY4R 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.